TY - JOUR
T1 - Recommendations for the clinical management of hepatitis C in Iran
T2 - A consensus-based national guideline
AU - Alavian, Seyed Moayed
AU - Hajarizadeh, Behzad
AU - Lankarani, Kamran Bagheri
AU - Sharafi, Heidar
AU - Daryani, Nasser Ebrahimi
AU - Merat, Shahin
AU - Mohraz, Minoo
AU - Mardani, Masoud
AU - Fattahi, Mohamad Reza
AU - Poustchi, Hossein
AU - Nikbin, Mehri
AU - Nabavi, Mahmood
AU - Adibi, Peyman
AU - Ziaee, Masood
AU - Behnava, Bita
AU - Rezaee-Zavareh, Mohammad Saeid
AU - Colombo, Massimo
AU - Massoumi, Hatef
AU - Bizri, Abdul Rahman
AU - Eghtesad, Bijan
AU - Amiri, Majid
AU - Namvar, Ali
AU - Hesamizadeh, Khashayar
AU - Malekzadeh, Reza
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Context: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. Evidence Acquisition: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, ScopusandWeb of Science. Expert opinionwasbasedonthe consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016. Results: Pegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. InHCVgenotype 1 and 4, DCV/SOF and LDV/SOF are recommended. InHCVgenotype 2, SOF plus RBV and inHCVgenotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered. Conclusions: Affordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection.
AB - Context: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. Evidence Acquisition: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, ScopusandWeb of Science. Expert opinionwasbasedonthe consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016. Results: Pegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. InHCVgenotype 1 and 4, DCV/SOF and LDV/SOF are recommended. InHCVgenotype 2, SOF plus RBV and inHCVgenotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered. Conclusions: Affordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection.
KW - Consensus
KW - Disease elimination
KW - Hepatitis C
KW - Iran
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84988577048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988577048&partnerID=8YFLogxK
U2 - 10.5812/hepatmon.guideline
DO - 10.5812/hepatmon.guideline
M3 - Review article
AN - SCOPUS:84988577048
SN - 1735-143X
VL - 16
JO - Hepatitis Monthly
JF - Hepatitis Monthly
IS - 8
M1 - e40959
ER -